Company Overview and News

169
Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

2018-06-21 seekingalpha
Anika Therapeutics (ANIK) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (‘OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combination anti-inflammatory formula that combines hyaluronic acid (‘HA) with a steroid (triamcinolone hexacetonide). HA serves as a lubricant for arthritic joints.
NTLA CYAD AMGN ANIK PSTI CRSP SRPT MDWD CANF AMPH NVUS RSLS ALXN ALNA KALA CYAD CLBS PRTA PSTIW

0
Prothena Announces Phase 1b Clinical Trial Results of PRX002/RG7935 for Parkinson's Disease Published in JAMA Neurology

2018-06-19 globenewswire
DUBLIN, Ireland, June 19, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that results from the Phase 1b multiple ascending dose study of PRX002/RG7935, an investigational monoclonal antibody for the potential treatment of Parkinson's disease, has been published in JAMA Neurology.
PRTA

0
PRTA / Prothena Corp plc FORM 8-K (Current Report)

2018-05-27 sec.gov
Document UNITED STATES
PRTA

5
PRTA / Prothena Corp plc FORM 8-K (Current Report)

2018-05-18 sec.gov
Document UNITED STATES
PRTA

106
Protalix: Valuable, Misunderstood, And Deeply Mispriced

2018-05-10 seekingalpha
Editor's note: Seeking Alpha is proud to welcome The Sensible Steward as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
CELG CF FOLD PRTA PFE CHRS

0
PRTA / Prothena Corp plc / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-05-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8) Prothena Corp plc (Name of Issuer) COMMON STOCK (Title of Class of Securities) G72800108 (CUSIP NUMBER) April 30, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
PRTA

0
PRTA / Prothena Corp plc / PRICE T ROWE ASSOCIATES INC /MD/ - null (Passive Investment)

2018-05-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8) Prothena Corp plc (Name of Issuer) COMMON STOCK (Title of Class of Securities) G72800108 (CUSIP NUMBER) April 30, 2018 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.
PRTA

3
PRTA / Prothena Corp plc FORM 10-Q (Quarterly Report)

2018-05-09 sec.gov
Document UNITED STATES
PRTA

3
PRTA / Prothena Corp plc FOM 8-K (Current Report)

2018-05-08 sec.gov
Document UNITED STATES
PRTA

1
Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update

2018-05-08 globenewswire
DUBLIN, Ireland, May 08, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan categories, today reported financial results for the first quarter of 2018. In addition, the Company provided an update on its R&D programs.
PRTA

179
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

2018-04-25 zacks
The biotech sector witnessed a series of events over the past week. Quite a few companies reported quarterly results over the week alongside announcing pipeline updates. Over the past week while Amgen revised its annual guidance, Biogen reported quarterly numbers wherein sales missed estimates.
CALA DDR AMGN GEC GE INCY DDR.PRJ BIIB DDR.PRK IONS DDR.PRA GNE PRTA

56
Prothena: A Compelling Bounce Play To At Least $15 And Not Unrealistic Buyout Target

2018-04-25 seekingalpha
I estimate that PRTA currently trades below its net cash value at a stock price of $11.50.
CELG PRTA

4
Prothena: What Now?

2018-04-24 seekingalpha
The stock of Prothena Corp. lost just over two thirds of its market value in trading Monday after terminating its lead drug program.
DB PRTA

267
Your Daily Pharma Scoop: Roche's Ocrevus, Biogen Data, Biohaven Update

2018-04-24 seekingalpha
Today we will discuss Roche (OTCQX:RHHBY), after the company announced data with its multiple sclerosis (MS) treatment Ocrevus from a long-term extension study. Ocrevus has seen strong uptake since its launch last year, and is expected to be a key value driver for Roche going forward.
AXSM PRTK RARE KMDA ABEO MLNT SAGE BHVN DVAX ACRS BIIB ABEOW PRTA PFE ALNY

2
Why Some Investors May Still Look at Prothena, But With Very Different Views

2018-04-23 247wallst
Creating a treatment for a rare disease or rare disorder can come with massive upside if the treatment is successful. That said, the risk is that a company can implode if its rare disease treatment fails in a drug study. Now it looks as if Prothena Corporation plc (NASDAQ: PRTA) is on the verge of implosion based upon how its stock price reacted.
PRTA

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

13h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: G72800108